Cancer
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
|
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) |
NIH |
05/20/2020 |
05/07/2023 |
|
|
Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed) |
NIH |
04/14/2020 |
06/24/2021 |
|
|
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) |
NIH |
03/30/2020 |
09/07/2022 |
|
|
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional) |
NIH |
03/16/2020 |
07/30/2021 |
|
|
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional) |
NIH |
03/16/2020 |
07/30/2021 |
|
|
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) |
NIH |
03/12/2020 |
05/07/2023 |
|
|
Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) |
NIH |
02/24/2020 |
11/18/2021 |
|
|
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) |
NIH |
01/27/2020 |
05/07/2023 |
|
|
Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional) |
NIH |
01/23/2020 |
11/18/2020 |
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) |
NIH |
01/23/2020 |
11/18/2020 |
|
|
Research Answers to National Cancer Institute's (NCI) Provocative Questions (R21 Clinical Trial Optional) |
NIH |
01/16/2020 |
11/17/2020 |
|
|
Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01 Clinical Trial Optional) |
NIH |
01/16/2020 |
11/17/2020 |
|
|
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21- Clinical Trial Not Allowed) |
NIH |
01/14/2020 |
04/01/2022 |
|
|
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed) |
NIH |
01/14/2020 |
04/01/2022 |
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) |
NIH |
12/20/2019 |
09/29/2020 |
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) |
NIH |
12/20/2019 |
09/29/2020 | |
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) |
NIH |
12/20/2019 |
09/29/2020 |
|
|
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) |
NIH |
12/10/2019 |
10/28/2022 |
|
|
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) |
NIH |
12/04/2019 |
09/29/2020 |
|
|
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) |
NIH |
12/04/2019 |
09/29/2020 |
|
|
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) |
NIH |
12/04/2019 |
09/29/2020 |
|
|
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) |
NIH |
12/04/2019 |
09/29/2020 |
|
|
Co-infection and Cancer (R21 Clinical Trial Not Allowed) |
NIH |
11/22/2019 |
01/07/2023 |
|
|
Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
NIH |
11/22/2019 |
01/07/2023 |
|
|
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed) |
NIH |
11/12/2019 |
01/07/2023 |
|
|
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) |
NIH |
11/08/2019 |
01/07/2023 |
|
|
Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional) |
NIH |
10/02/2019 |
01/07/2023 |
|
|
Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional) |
NIH |
10/02/2019 |
01/07/2023 |
|
|
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) |
NIH |
09/12/2019 |
01/07/2023 |
|
|
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) |
NIH |
09/05/2019 |
05/07/2021 |
|
|
Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed) |
NIH |
09/05/2019 |
06/23/2021 |
|
|
Revision Applications for Mechanisms of Drug Resistance (P50 Clinical Trials Not Allowed) |
NIH |
09/05/2019 |
06/23/2021 |
|
|
Revision Applications for Mechanisms of Drug Resistance (P01 Clinical Trials Not Allowed) |
NIH |
09/05/2019 |
06/23/2021 |
|
|
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional) |
NIH |
08/29/2019 |
07/16/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
NIH |
08/28/2019 |
07/20/2022 |
|
|
Neural Regulation of Cancer (R21 Clinical Trial Not Allowed) |
NIH |
08/28/2019 |
05/27/2022 |
|
|
Neural Regulation of Cancer (R01 Clinical Trial Not Allowed) |
NIH |
08/28/2019 |
05/27/2022 |
|
|
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) |
NIH |
08/16/2019 |
06/08/2022 |
|
|
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) |
NIH |
08/16/2019 |
06/08/2022 | |
| PAR-19-339 | Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional) | NIH | 08/12/2019 | 06/08/2022 |
| PAR-19-340 | Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional) | NIH | 08/12/2019 | 06/08/2022 |
|
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) |
NIH |
07/30/2019 |
02/11/2022 |
|
|
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) |
NIH |
06/28/2019 |
09/07/2022 |
|
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional) |
NIH |
04/11/2019 |
11/08/2021 |
|
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional) |
NIH |
04/11/2019 |
11/08/2021 |
|
|
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) |
NIH |
03/13/2019 |
10/18/2020 |
|
|
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) |
NIH |
02/27/2019 |
11/08/2021 |
|
|
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed) |
NIH |
02/27/2019 |
11/08/2021 |
|
|
Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) |
NIH |
02/22/2019 |
05/07/2022 |
|
|
Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) |
NIH |
02/22/2019 |
05/07/2022 |
|
|
Biology of Bladder Cancer (R21 Clinical Trial Optional) |
NIH |
02/05/2019 |
05/07/2022 |
|
|
Biology of Bladder Cancer (R01 Clinical Trial Optional) |
NIH |
02/05/2019 |
05/07/2022 |
|
|
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional) |
NIH |
01/24/2019 |
08/03/2020 |
|
|
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) |
NIH |
12/17/2018 |
01/07/2022 |
|
|
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional) |
NIH |
12/17/2018 |
01/07/2022 |
|
|
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional) |
NIH |
12/17/2018 |
01/07/2022 |
|
|
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21 Clinical Trial Not Allowed) |
NIH |
10/5/2018 |
3/4/2021 |
|
|
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 Clinical Trial Not Allowed) |
NIH |
10/5/2018 |
3/4/2021 |
|
|
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed) |
NIH |
9/5/2018 |
11/13/2020 |
|
|
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional) |
NIH |
8/7/2018 |
9/7/2021 |
|
|
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional) |
NIH |
8/7/2018 |
9/7/2021 |
|
|
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) |
NIH |
7/24/2018 |
3/8/2021 |
|
|
The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed) |
NIH |
6/14/2018 |
6/3/2021 |
|
|
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) |
NIH |
3/29/2018 |
11/19/2020 |
|
|
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 - Clinical Trial Not Allowed) |
NIH |
2/23/2018 |
5/7/2021 |
|
|
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed) |
NIH |
2/23/2018 |
5/7/2021 |
|
|
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) |
NIH |
2/5/2018 |
5/7/2021 |
|
|
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required) |
NIH |
1/5/2018 |
1/7/2021 |
|
|
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) |
NIH |
1/5/2018 |
1/7/2021 |
|
|
Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed) |
NIH |
12/20/2017 |
1/7/2021 |
|
|
Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed) |
NIH |
12/20/2017 |
1/7/2021 |
|
|
Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed) |
NIH |
12/20/2017 |
1/7/2021 |
|
|
Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R01 Clinical Trial Optional) |
NIH |
12/11/2017 |
5/7/2021 |
|
|
Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional) |
NIH |
12/11/2017 |
5/7/2021 |
|
|
The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) |
NIH |
12/6/2017 |
3/12/2021 |
|
|
The NCI Transition Career Development Award (K22 Independent Clinical Trial Required) |
NIH |
12/6/2017 |
3/12/2021 |
|
|
Cancer Research Education Grants Program - Curriculum or Methods Development (R25) |
NIH |
12/5/2017 |
1/7/2021 |
|
|
Cancer Research Education Grants Program - Courses for Skills Development (R25) |
NIH |
12/5/2017 |
1/7/2021 |
|
|
Cancer Research Education Grants Program - Research Experiences (R25) |
NIH |
12/5/2017 |
1/7/2021 |
|
|
NCI Mentored Research Scientist Development Award to Promote Diversity (K01) |
NIH |
11/17/2017 |
1/7/2021 |
|
|
NCI Mentored Research Scientist Development Award to Promote Diversity (K01) |
NIH |
11/17/2017 |
1/7/2021 |
|
|
NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) |
NIH |
11/21/2017 |
1/7/2021 |
|
|
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50) |
NIH |
10/12/2017 |
1/7/2021 |
|
|
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - No Independent Clinical Trials) |
NIH |
10/31/2017 |
1/7/2021 |
|
|
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Clinical Trials Required) |
NIH |
10/31/2017 |
1/7/2021 |
|
|
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) |
NIH |
8/4/2017 |
9/7/2020 |
|
|
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01) |
NIH |
8/4/2017 |
9/7/2020 |
|
|
Biology of Lung, and Head and Neck Preneoplasias (R01) |
NIH |
8/15/2017 |
1/7/2021 |
|
|
Biology of Lung, and Head and Neck Preneoplasias (R21) |
NIH |
8/16/2017 |
1/7/2021 |
|
|
Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01) |
NIH |
7/20/2017 |
9/7/2020 |
|
|
Integration of Individual Residential Histories into Cancer Research (R21) |
NIH |
6/22/2017 |
9/7/2020 |
|
|
Integration of Individual Residential Histories into Cancer Research (R01) |
NIH |
6/22/2017 |
9/7/2020 |
|
|
Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01) |
NIH |
5/16/2017 |
9/7/2020 |
|
|
Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21) |
NIH |
5/16/2017 |
9/7/2020 |
|
|
Mechanisms of Alcohol-associated Cancers (R01) |
NIH |
3/13/2017 |
9/7/2020 |
|
|
Mechanisms of Alcohol-associated Cancers (R21) |
NIH |
3/13/2017 |
9/7/2020 |